129 related articles for article (PubMed ID: 37478615)
1. Clinical significance of L1CAM expression in metastatic tubo-ovarian high-grade serous carcinoma.
Dos Santos MV; Holth A; Lindemann K; Staff AC; Davidson B
Gynecol Oncol; 2023 Sep; 176():76-81. PubMed ID: 37478615
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological prognostic parameters in patients with tubo-ovarian carcinoma effusions.
Davidson B; Elstrand MB
Cytopathology; 2022 Jul; 33(4):479-492. PubMed ID: 35398934
[TBL] [Abstract][Full Text] [Related]
3. Occludin is overexpressed in tubo-ovarian high-grade serous carcinoma compared to mesothelioma and is a marker of tumor progression and chemoresistance.
Dos Santos MV; Holth A; Bischof K; Davidson B
Clin Exp Metastasis; 2024 Feb; 41(1):69-76. PubMed ID: 38141113
[TBL] [Abstract][Full Text] [Related]
4. Claudin-10 is a new candidate prognostic marker in metastatic high-grade serous carcinoma.
Davidson B; Doutel D; Holth A; Nymoen DA
Virchows Arch; 2023 Jun; 482(6):975-982. PubMed ID: 37067588
[TBL] [Abstract][Full Text] [Related]
5. Expression of palladin is associated with disease progression in metastatic high-grade serous carcinoma.
Davidson B; Bock AJ; Holth A; Nymoen DA
Cytopathology; 2020 Nov; 31(6):572-578. PubMed ID: 32741023
[TBL] [Abstract][Full Text] [Related]
6. Death domain-associated protein (DAXX) expression is associated with poor survival in metastatic high-grade serous carcinoma.
Davidson B; McFadden E; Holth A; Brunetti M; Flørenes VA
Virchows Arch; 2020 Dec; 477(6):857-864. PubMed ID: 32533344
[TBL] [Abstract][Full Text] [Related]
7. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival.
Davidson B; Trope' CG; Wang TL; Shih IeM
Gynecol Oncol; 2006 Dec; 103(3):814-9. PubMed ID: 16844205
[TBL] [Abstract][Full Text] [Related]
8. HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival.
Davidson B; Holth A; Hellesylt E; Hadar R; Katz B; Tropé CG; Reich R
Hum Pathol; 2016 Feb; 48():95-101. PubMed ID: 26640230
[TBL] [Abstract][Full Text] [Related]
9. TGFβ splicing and canonical pathway activation in high-grade serous carcinoma.
Gutgold N; Davidson B; Catane LJ; Holth A; Hellesylt E; Tropé CG; Dørum A; Reich R
Virchows Arch; 2017 Jun; 470(6):665-678. PubMed ID: 28432432
[TBL] [Abstract][Full Text] [Related]
10. SOX2 and SOX9 are markers of clinically aggressive disease in metastatic high-grade serous carcinoma.
Sherman-Samis M; Onallah H; Holth A; Reich R; Davidson B
Gynecol Oncol; 2019 Jun; 153(3):651-660. PubMed ID: 30904337
[TBL] [Abstract][Full Text] [Related]
11. The phosphatase PTPN1/PTP1B is a candidate marker of better chemotherapy response in metastatic high-grade serous carcinoma.
Davidson B; Bock AJ; Holth A; Nymoen DA
Cytopathology; 2021 Mar; 32(2):161-168. PubMed ID: 33025675
[TBL] [Abstract][Full Text] [Related]
12. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
[TBL] [Abstract][Full Text] [Related]
13. HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival.
Stavnes HT; Holth A; Don T; Kærn J; Vaksman O; Reich R; Trope' CG; Davidson B
Gynecol Oncol; 2013 May; 129(2):358-63. PubMed ID: 23438671
[TBL] [Abstract][Full Text] [Related]
14. Expression of Wnt pathway molecules is associated with disease outcome in metastatic high-grade serous carcinoma.
Chehover M; Reich R; Davidson B
Virchows Arch; 2020 Aug; 477(2):249-258. PubMed ID: 31900634
[TBL] [Abstract][Full Text] [Related]
15. Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance.
Hetland TE; Hellesylt E; Flørenes VA; Tropé C; Davidson B; Kærn J
Hum Pathol; 2011 Jul; 42(7):1019-26. PubMed ID: 21315408
[TBL] [Abstract][Full Text] [Related]
16. Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival.
Brenne K; Nymoen DA; Hetland TE; Trope' CG; Davidson B
Hum Pathol; 2012 Apr; 43(4):496-505. PubMed ID: 21855111
[TBL] [Abstract][Full Text] [Related]
17. Expression of the cancer stem cell marker SSEA1 is associated with poor survival in metastatic high-grade serous carcinoma.
Davidson B; Holth A; Dong HP
Virchows Arch; 2020 Nov; 477(5):677-685. PubMed ID: 32472195
[TBL] [Abstract][Full Text] [Related]
18. Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma.
Onallah H; Catane LJ; Tropé CG; Hetland Falkenthal TE; Reich R; Davidson B
Virchows Arch; 2018 Oct; 473(4):463-470. PubMed ID: 30032361
[TBL] [Abstract][Full Text] [Related]
19. TSAP6 is a novel candidate marker of poor survival in metastatic high-grade serous carcinoma.
Broner EC; Tropé CG; Reich R; Davidson B
Hum Pathol; 2017 Feb; 60():180-187. PubMed ID: 27825812
[TBL] [Abstract][Full Text] [Related]
20. Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion.
Davidson B; Smith Y; Nesland JM; Kærn J; Reich R; Tropè CG
Hum Pathol; 2013 Nov; 44(11):2449-60. PubMed ID: 24011953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]